BIOChecker4
2 minutes ago
If Missling focused on just two or three programs addressing rare diseases, funded and conducted clinical trials the right way, and produced credible results in a timely manner, big investors (and potential pharma partners) would be pounding down the door to give him money. Instead, he has to raise